ECSP045200A - Acidos 3-(imidazolil)-2-alcoxipropanoicos - Google Patents
Acidos 3-(imidazolil)-2-alcoxipropanoicosInfo
- Publication number
- ECSP045200A ECSP045200A EC2004005200A ECSP045200A ECSP045200A EC SP045200 A ECSP045200 A EC SP045200A EC 2004005200 A EC2004005200 A EC 2004005200A EC SP045200 A ECSP045200 A EC SP045200A EC SP045200 A ECSP045200 A EC SP045200A
- Authority
- EC
- Ecuador
- Prior art keywords
- alcoxipropanoicos
- imidazolil
- acids
- alkyl
- hydrogen
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- -1 aromatic heterocycle Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de acuerdo con la fórmula (I) en la que n es 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7, R8 y R9 se selecciona independientemente entre hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5 y R8 son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patologías asociadas con la deposición de fibrina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045200A true ECSP045200A (es) | 2004-08-27 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005200A ECSP045200A (es) | 2002-01-22 | 2004-07-22 | Acidos 3-(imidazolil)-2-alcoxipropanoicos |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (es) |
| JP (1) | JP2005520811A (es) |
| KR (1) | KR20040077775A (es) |
| CN (1) | CN1620291A (es) |
| AP (1) | AP2004003084A0 (es) |
| AR (1) | AR038197A1 (es) |
| BR (1) | BR0307016A (es) |
| CA (1) | CA2472238A1 (es) |
| EA (1) | EA200400716A1 (es) |
| EC (1) | ECSP045200A (es) |
| HR (1) | HRP20040659A2 (es) |
| IL (1) | IL162677A0 (es) |
| IS (1) | IS7310A (es) |
| MA (1) | MA27167A1 (es) |
| MX (1) | MXPA04006573A (es) |
| NO (1) | NO20043457L (es) |
| OA (1) | OA12756A (es) |
| PA (1) | PA8563501A1 (es) |
| PE (1) | PE20030929A1 (es) |
| PL (1) | PL371487A1 (es) |
| TN (1) | TNSN04121A1 (es) |
| TW (1) | TW200302094A (es) |
| UY (1) | UY27615A1 (es) |
| WO (1) | WO2003061652A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| US20060234986A1 (en) * | 2005-04-18 | 2006-10-19 | Schering Aktiengesellschaft | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI |
| NZ592764A (en) | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| WO2010065717A1 (en) * | 2008-12-05 | 2010-06-10 | Mochida Pharmaceutical Co., Ltd. | Morpholinone compounds as factor ixa inhibitors |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| CA2791505C (en) | 2010-03-18 | 2016-06-07 | Daiichi Sankyo Company, Limited | Cycloalkyl-substituted imidazole derivative |
| CN102884053B (zh) * | 2010-03-18 | 2016-03-02 | 第一三共株式会社 | 环丙烷甲酸衍生物 |
| JP6461113B2 (ja) | 2013-06-10 | 2019-01-30 | サノフイＳａｎｏｆｉ | ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用 |
| US20190117624A1 (en) | 2016-03-29 | 2019-04-25 | Daiichi Sankyo Company, Limited | Therapeutic agent for inflammatory bowel diseases |
| DK3682881T3 (da) | 2017-09-14 | 2026-05-11 | Daiichi Sankyo Co Limited | Forbindelse med cyklisk struktur |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| SI1311488T1 (sl) * | 2000-08-17 | 2010-01-29 | Pfizer Ltd | Substituirani imidazoli kot inhibitorji TAFIA |
-
2003
- 2003-01-10 HR HR20040659A patent/HRP20040659A2/hr not_active Application Discontinuation
- 2003-01-10 EA EA200400716A patent/EA200400716A1/ru unknown
- 2003-01-10 CA CA002472238A patent/CA2472238A1/en not_active Abandoned
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/es unknown
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/en not_active Ceased
- 2003-01-10 EP EP03700059A patent/EP1467731A1/en not_active Withdrawn
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/zh active Pending
- 2003-01-10 IL IL16267703A patent/IL162677A0/xx unknown
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/pt not_active IP Right Cessation
- 2003-01-10 PL PL03371487A patent/PL371487A1/xx unknown
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/ko not_active Ceased
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/ja active Pending
- 2003-01-16 TW TW092100889A patent/TW200302094A/zh unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/es not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/es not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/es unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/es unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/is unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/fr unknown
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/es unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27615A1 (es) | 2003-08-29 |
| CA2472238A1 (en) | 2003-07-31 |
| KR20040077775A (ko) | 2004-09-06 |
| MXPA04006573A (es) | 2004-10-04 |
| OA12756A (en) | 2006-07-03 |
| HRP20040659A2 (en) | 2004-10-31 |
| BR0307016A (pt) | 2004-11-03 |
| PA8563501A1 (es) | 2004-08-31 |
| JP2005520811A (ja) | 2005-07-14 |
| NO20043457L (no) | 2004-08-19 |
| CN1620291A (zh) | 2005-05-25 |
| AR038197A1 (es) | 2005-01-05 |
| EA200400716A1 (ru) | 2004-12-30 |
| EP1467731A1 (en) | 2004-10-20 |
| TNSN04121A1 (en) | 2006-06-01 |
| MA27167A1 (fr) | 2005-01-03 |
| WO2003061652A8 (en) | 2004-09-10 |
| TW200302094A (en) | 2003-08-01 |
| WO2003061652A1 (en) | 2003-07-31 |
| IS7310A (is) | 2004-06-14 |
| PL371487A1 (en) | 2005-06-13 |
| AP2004003084A0 (en) | 2004-09-30 |
| IL162677A0 (en) | 2005-11-20 |
| PE20030929A1 (es) | 2003-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27522A1 (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| CY1107903T1 (el) | Παραγωγα ακυλαμινοθειαζολης και η χρηση τους ως αναστολεις του βητα-αμυλοειδους | |
| PE20050999A1 (es) | Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| PE20070078A1 (es) | Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa | |
| ATE404538T1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität | |
| ECSP045369A (es) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| PE20050226A1 (es) | Productos aril-heteroaromaticos y composiciones que los contienen | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| CO5580762A2 (es) | Analogos de lipoxina a4 | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| UY27615A1 (es) | Acidos 3 - (imidazolil) - 2 alcoxipropanoicos | |
| PE20050231A1 (es) | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 | |
| PE20040528A1 (es) | Inhibidores de la peptido-deformilasa | |
| MXPA04005940A (es) | Acidos 3-(imidazolil)-2-aminopropanoicos. | |
| PE20050120A1 (es) | Camptotecinas con un anillo de lactona modificada | |
| AR040140A1 (es) | Derivados de esteres de camptotecina en la posicion 20 | |
| PE20030611A1 (es) | Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones | |
| DE60124717D1 (de) | Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit | |
| AR053339A1 (es) | Composiciones para el tratamiento del cabello y/o del cuero cabelludo | |
| DOP2003000564A (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos | |
| BRPI0508471A (pt) | hidróxi-6-fenilfenantridinas substituìdas por difluoroetóxi | |
| PE20010165A1 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano como antagonistas de la sustancia p |